CN1895669A - Mucosa-immune composite adjuvant - Google Patents
Mucosa-immune composite adjuvant Download PDFInfo
- Publication number
- CN1895669A CN1895669A CN 200610085420 CN200610085420A CN1895669A CN 1895669 A CN1895669 A CN 1895669A CN 200610085420 CN200610085420 CN 200610085420 CN 200610085420 A CN200610085420 A CN 200610085420A CN 1895669 A CN1895669 A CN 1895669A
- Authority
- CN
- China
- Prior art keywords
- mucosa
- immune
- adjuvant
- immunity
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
A compound adjuvant for the mucosa immunization of oral vaccine is proportionally composed of oligodeoxynucleotide (CpG) DNA and sodium fluoride. It can improve the immunological competence and decrease the dosage of Newcastle disease IV vaccine.
Description
One, technical field
The present invention relates to a kind of composite adjuvant of mucosa-immune, belong to biological technical field.Be exclusively used in the immune effect of the mucosa-immune of vaccine.
Two, background technology
The characteristics of 1 digestive tract mucosa-immune
The mucosa-immune system is meant the immunity of tract (comprising respiratory tract, digestive tract and the urogenital tract) mucous membrane surface that body communicates with the external world.This system area coverage in vivo is very big (to surpass 400m
2), form the first road barrier that animal body is defendd extraneous pathogen, so the mucosa-immune system occupies important status in body immune system.The digestive tract lymphoid tissue also claims gut associated lymphoid tissue (GALT).Secretory IgA is the main effects factor of mucosa-immune, and it not only has neutralization virus, suppresses the effect of microorganism absorption, also has the function of the immunologic rejection and the short natural antibacterial factor.
The mucosa-immune system import into inductive site for send the Yi Ershi speckle (Peyer ' s Patches, PP) and lymph follicle, PP is positioned at the ileal mucosa lamina propria and is deep into Submucosa, the PP of chicken is a pink elliptical spot, is positioned at back above the blind intersection.PP is divided into three districts: 1. dermatotome on the specialization dome, 2. folliculus district or B cellular regions, 3. other district of folliculus or T cellular regions.There is the antigen recognition cell of particularization in the dermatotome or claims the M cell on the dome, and it gulps down multiple antigen in the drink enteric cavity.Antigen is transported to PP, and the district is subject to processing at folliculus, causes antigen-specific b and the excitement of T lymphocyte.They leave PP subsequently, transfer to mucosa lamina propria and intraepithelial lymphocyte.T cell in the PP can activate the B cell, produces IgA.
The effector that spreads out of of mucosa-immune system is divided into lamina propria and intraepithelial lymphocyte.During normal condition, the intestinal mucosa lamina propria contains a large amount of plasma cells constantly, wherein 70%～90% secretion IgA.Plasmacytic precursor is from PP in the lamina propria, by mesentery lymph and thoracic duct to the mucosa lamina propria.Macrophage accounts for 10% of lamina propria endolymph cell.Studies show that, intraepithelial lymphocyte has the activity of cytotoxic activity and natural killer lymphocyte, can secrete the various kinds of cell factor, participate in the formation of intestinal anti-infectious immunity and peroral immunity tolerance, and play an important role in adjusting intestinal mucosa epithelial cell function aspects.Little gauffer cell (Microfold cell) is called for short the M cell, is a kind of flat epithelial cell of specialization, closely is arranged in enterocyte.The M cytoplasm has abundant gulping down and drinks vesicle and mitochondrion.Also there is the M cell in the PP place of chicken, and has very strong drink liquid activity.The M cell mainly absorbs and transport particles antigen, as antigenicity substances such as some virus, antibacterials.
The effect site of mucosa-immune also is to induce the site, the B cell is subjected to forming the lymphocyte of sensitization by systemic circulation also spreadable other mucosa effect site (as mammary gland, bronchial mucosa, reproductive tract mucosa etc.) of arriving except that being distributed to digestive tract again after the antigenic stimulus among the digestive tract PP, the B cell carries out clonal expansion at these positions, in case touch same antigen again, assisting down of Th cell and its excretory cytokine, be divided into the plasma cell of secretion IgA.
The progress of 2 mucosa-immune adjuvants
At present, the mucosa-immune adjuvant has become one of research focus of mucosa-immune, and it not only can cause the immunoreation of local and whole body.Study main type antibacterial adjuvant, Nuclec acid adjuvants, cytokine adjuvant, inorganic constituents adjuvant and delivery system are arranged.
Discover and contain special nucleotide sequence in the bacillus calmette-guerin vaccine---the CpG motif, can specific increase immunogenicity of antigens.DNA, the plasmid DNA of antibacterial and the oligonucleotide of synthetic of methylated CpG motif are referred to as CpG DNA containing not at present, be Nuclec acid adjuvants or DNA sequence (immunostimulatorysequences with immunostimulation, ISS), when the vaccine with them and proteantigen uses jointly, can induce immunoreation based on cellular immunization.Experiment confirm, CpG oligodeoxynucleotide (CpG-ODN) can promote system and the mucosal immune response of body to hbs antigen (HbsAg) as the mucosa adjuvant.CpG DNA can improve the shortcoming that other adjuvant induces the Th2 type to reply, and as adjuvant couplings such as CpG-ODN and CT or aluminium hydroxide, the Th1 and the Th2 class that induce mixed type are earlier replied, and turn to replying of Th1 type then.
Cytokine is the body immune regulator that the T lymphocyte produces when immunoreation, bacteriotoxin and CpG are by cytokine performance adjuvant effect, and most cytokines has the ability of adjusting and rebuilding immunne response, therefore can directly play a role as adjuvant.What experimentize research at present mainly contains IL-1, IL-2, IL-6, IL-12, IFN-γ, GM-CSF etc.IL-2 is the important regulatory factor of immunne response in the animal body, has characteristics such as pleiotropy, high efficiency and reaction are fast, can improve immunologic function, and multiple antigen is all had potentiation.IL-2 plays pivotal role in lymphocytic breeding, can excite and safeguard lymphocytic growth, finally causes lymphocytic differentiation and propagation, keeps immunologic homeostasis.
Use fluoride as the existing report of the research of mucosa-immune adjuvant.Sumio etc. discover that mucosa adjuvant NaF can eliminate oral tolerance, cause that antibody response increases.Behind chicken while oral antigen and the NaF, the serum IgG antibody level obviously increases.Although the chicken group has individual variation, and antibody titer is lower, all detects IgA antibody in bile and tear.Aluminium fluoride can induce that the polyphosphoric acids inositol is degraded to phosphoinositide in the rat T cell, free Ca2+ in the rising cell, and make the γ of TXi Baoshouti and ε chain carry out phosphorylation, thus the T cell enters activatory commitment.In addition, synthetic polymer and lipotropy quaternary ammonium salt also can be used as the mucosa adjuvant.
Phytoestrogen-daidzein is a kind of plant isoflavonoid that is present in the leguminous plant, has the dual function of estrogen-like or estrogen antagonist sample.Studies show that phytoestrogen all has in various degree influence to nonspecific immunity, cellular immunization and the humoral immunization of body.Phytoestrogen can influence the phagocytic function of macrophage.Peaks etc. find that the immune organ thymus of chickling and the relative weight of fabricius bursa significantly improve add daidzein in the basal diet of young cock after, spleen does not have significant change, the T lymphocyte significantly improves the irritant reaction of phytohaemagglutinin (PHA) simultaneously, illustrates that young cock cellular immunization strengthens.If daidzein can be used as the mucosa-immune adjuvant, not only can improve the production capacity of animal, the infectious disease that can also prevent poultry.
The meaning of 3 mucosa-immune adjuvants in the digestive tract mucosa-immune
Zoonotic propagation is a main path with digestive tract and respiratory tract all mostly.Oral attenuated vaccine can directly stimulate the lymphocyte in the small intestinal mucosa to produce a large amount of IgA and the various kinds of cell factor, forms layer protecting film on the intestinal mucosa surface, the invasion of defence pathogenic microorganism.Research not only produces immunne response in mucosa part and other mucous membrane tissue with facts have proved the digestive tract mucosa-immune, also can cause the humoral immunoresponse(HI) of general, so mucosa-immune receives domestic and international immunologist's concern.Digestive tract immunity (oral immunity) method is easy, time saving and energy saving, can not cause the stress of animal during operation, is specially adapted to the immunity inoculation of the meiofauna of large-scale farming.But vaccine process digestive tract is subjected to the degraded of Digestive system often, and the antigen amount that mucosa-immune is needed is more than traditional intramuscular injection.Therefore, how to use a spot of antigen to induce the mucosa-immune reaction effectively, improve mucosa-immune power and become present urgent problem.Immunological adjuvant is to mix the material that can promote, prolong or strengthen behind the bacterin preparation the vaccine antigen specific immune response.Foreign study is found in recent years, and the immunity that the mucosa-immune adjuvant can enhancing body obviously improves the immune effect of the local and system of mucosa.
Along with the continuous development of aviculture, effective vaccine safe in utilization is controlled the propagation of fowl infection and is developed most important.Mucosa-immune is compared simple and safe, time saving and energy saving with traditional intramuscular injection, reduce the stress of poultry, avoids the influence to increasing weight and laying eggs, and is suitable for raising chickens on a large scale.Simultaneously, vaccine only acts on the digestive tract mucous membrane tissue (all being abandoned in these positions) of poultry during owing to the drinking-water immunity in the processing of poultry meat product, can not produce bigger influence to the quality of birds product, thereby help the outlet of China's chicken meat product.For this method is applied, it is basic premise that good immune effect is arranged.The application of composite mucosa immunological adjuvant can improve immune effect, reduces the immune cost of aquaculture simultaneously.
Three, summary of the invention
Technical problem
The composite adjuvant that the purpose of this invention is to provide a kind of mucosa-immune is used for enhancing body mucosa-immune power and general immunity power and the complex immunity adjuvant that adds when using the oral vaccine immunity.
Technical scheme
The composite adjuvant that the invention provides a kind of mucosa-immune is to use the immunological adjuvant prescription to be by the body weight per kilogram: 20～100 μ g oligodeoxynucleotide (CpG) DNA+2～10mg sodium fluoride.The chickling consumption by every is: 20～100 μ g oligodeoxynucleotide (CpG) DNA+2～10mg sodium fluoride.
Beneficial effect
1, the present invention is in vaccine cooperates by drinking-water immunity back detection chicken body on the immunoreactive basis with newcastle IV respectively using several mucosa-immune reinforcing agents (daidzein, chicken host lactobacillus, oligodeoxynucleotide DNA, recombinant il-2 and sodium fluoride), filter out immune effect preferably the mucosa-immune reinforcing agent carry out composite, composite good immunity composite adjuvant is that vaccine cooperates with newcastle IV again, detects local mucosa-immune reaction of chicken small intestinal and systemic immune response by the immunity back of drinking water.Comprise CD3 in the small intestinal by detecting the mucosa-immune reaction
+T cell, intraepithelial lymphocyte and IgA secretory cell quantity, jejunum interferon-mRNA level changes; Systemic immune response comprises the variation of SIgA antibody horizontal in the newcastle specific antibody and small intestine contents in the serum, finds that the composite mucosa immunological adjuvant has significantly improved animal immunizing power.
2, the characteristics of composite mucosa immunological adjuvant of the present invention are: the advantage that combines single adjuvant; the increase vaccine immunity protection period reaches nearly 3 months; simplify immune programme for children; China tradition newcastle disease prevention take the to drink water method that combines with intramuscular injection is simplified to and only needs drinking-water immune, significantly improve animal immunizing power.
3, reduce the vaccine consumption, will need 2～4 times with the pro-antigen amount and be reduced to 1 times, the immunity inoculation cost has reduced by 3.125%.
Four, description of drawings
ND specific antibody level in the single immunological adjuvant serum of Fig. 1
The duodenal IgA secretory cell of the single immunological adjuvant of Fig. 2-1 number change
The IgA secretory cell number change of the single immunological adjuvant jejunum of Fig. 2-2
The IgA secretory cell number change of the single immunological adjuvant Peyer ' of Fig. 2-3 s speckle
ND specific antibody level in Fig. 3 composite adjuvant serum
The duodenal CD3 of Fig. 4-1 composite adjuvant
+The T cell quantity changes
The CD3 of Fig. 4-2 composite adjuvant jejunum
+The T cell quantity changes
The duodenal IgA secretory cell of Fig. 5-1 composite adjuvant number change
The IgA secretory cell number change of Fig. 5-2 composite adjuvant jejunum
Fig. 6-1 composite adjuvant jejunum SIgA level changes
The SIgA level changes in Fig. 6-2 composite adjuvant feces
Fig. 7 composite adjuvant is to PCR electrophoretogram (a is 18S, and b the is IFN-γ) M of chicken jejunum IFN-γ mRNA influence, and DNA standard molecular weight DL2000 swimming lane 1 is an aggregate sample; Swimming lane 2-4,5-7,8-10 are the 3rd, 5,7 all samples, group is followed successively by: contrast, ND, composite adjuvant group
Fig. 8 composite adjuvant jejunum IFN-γ/18S PCR electrophoretogram statistical result
Fig. 9 composite adjuvant immunity chicken is to the attack survival rate of Avian pneumo-encephalitis virus F48E2 virulent strain
Five, the specific embodiment
At first, this project has been carried out first phase test.It is (public to use chicken host lactobacillus according to schedule respectively, document sees reference: Yu Zhuoteng, Mao Shengyong, the antibacterial ability of Zhu Wei cloud Intestinum Gallus domesticus mucosa lactobacillus and to the susceptibility characteristic Hua Zhong Agriculture University journal 2,005 24 (4) of antibiotics: 376～379), sodium fluoride, recombinant il-2 is (public, document sees reference: Li Xiangrui, golden red, the good chicken interleukin-2 cDNA clone of Lu Jing Agricultural University Of Nanjing journal 1999,22 (2): 80～84), oligodeoxynucleotide DNA (CpG DNA, public, document sees reference: Cui Yibang, what Kong Wang, Lu Chengping, Guo likes that precious antibacterial CpGDNA is to the immunological enhancement of chicken inoculation bird flu virus H9 hypotype inactivated vaccine China veterinary journal 2,005 25 (2): 135～137) and daidzein (available from Xuan Hua chemical plant, Zhangjiakou) be that mucosa-immune adjuvant and newcastle disease IV are that (JAAS herds (2000) No. 003 Seedling, available from academy of agricultural sciences, Jiangsu Province animal and veterinary institute) cooperate, by the drinking-water immunized chicks, exempt from back the 3rd at head, 5,7 weeks drew materials.Detected in the chicken serum variation of mastocyte quantity in the variation of IgA secretory cell number change, Peyer ' s speckle intraepithelial lymphocyte quantity in newcastle specific antibody level, the small intestinal and the small intestinal respectively, SIgA level in the intestinal contents.The level (Fig. 1) that it is vaccine that the newcastle serological specificity antibody horizontal that found that daidzein, interleukin and sodium fluoride all is higher than independent use newcastle IV.Lactobacillus, CpG DNA, daidzein and recombinant il-2 all can significantly increase IgA secretory cell quantity in each section small intestinal in whole duration of immunity, in the 3rd week after immunity, the IgA secretory cell quantity of lactobacillus and recombinant il-2 is maximum; In immunity the 7th week of back, the IgA secretory cell quantity of daidzein and CpG DNA is (Fig. 2-1, Fig. 2-2, Fig. 2-3) at most.Daidzein, CpG DNA and recombinant il-2 can increase Peyer ' s speckle place intraepithelial lymphocyte quantity.Daidzein, CpGDNA, recombinant il-2, sodium fluoride and lactobacillus all can cause the temporary increase of each section small intestinal mastocyte quantity.Show that used several mucosa-immune adjuvant can increase body systemic immune response, the reaction of small intestinal local immunity and local anaphylaxis reaction in various degree.
Carry out according to the characteristics of above several mucosa-immune adjuvants composite, preparation composite mucosa immunological adjuvant (every chicken: 20～100 μ g CpG DNA+2～10mg sodium fluoride) mix with newcastle disease vaccine, during test chicken 7 ages in days the first time oral immunity, immunizing dose (10
6EID
50/ plumage) is normal amount of drinking water.Booster immunization after 7 days, dosage is the same.After the first immunisation the 3rd, 5,7 weeks draw materials.Detect in the serum intraepithelial lymphocyte number change, mastocyte (Toluidine blue staining) number change, IgA secretory cell number change, small intestinal CD3 in newcastle specific antibody IgG level (Fig. 3), the small intestinal respectively
+SIgA level in the variation of T cell quantity and interferon-mRNA expression and the intestinal contents.Discover that this composite adjuvant can significantly increase the CD3 of vaccinated flock
+T cell (Fig. 4-1, Fig. 4-2), quantity (Fig. 5-1 of intraepithelial lymphocyte and IgA secretory cell, Fig. 5-2), SIgA antibody horizontal (Fig. 6-1 in newcastle specific antibody and the small intestine contents in the raising immune chicken serum, Fig. 6-2), interferon-mRNA expression (Fig. 7,8) on a declining curve in the chicken jejunum tissue.In challenge test, can effectively protect vaccinated flock, protective rate reach 100% (table 1, Fig. 9).Show that the composite mucosa immunological adjuvant can effectively improve local mucosa-immune power of vaccinated flock and whole body humoral immunity level, effectively protects the chicken group.
1 cellular immune level detects
1) small intestinal CD3
+The variation of T cell quantity
Detect CD3 with the ABC method
+The T cell: section is fixedly inserted 0.6%H behind the 10min in paraformaldehyde
2O
2Handle 30min, with 0.2%Triton PBS (PH7.6) washing 3 times, each 5min; Through 5% normal sheep serum sealing 20min, room temperature; Directly add the suitably mouse-anti chicken CD3 of dilution after abandoning sheep blood serum, 4 ℃ are spent the night; Wash the same, add 1: 1 the dilution sheep anti-mouse igg, 37 ℃ the effect 60min; Wash the same, add 1: 2 the dilution S-A/HRP, 37 ℃ the effect 40min; 0.2%TritonPBS (PH7.6) washing 2 times, each 5min, Tris-HCl buffer (0.05molL
-1, pH7.6) washing is 3 times, each 5min, DAB (Sigma company) H
2O
2Colour developing; Dehydration; Transparent; Sealing.The Olympus microscopic examination, take pictures.Matched group substitutes mouse-anti chicken CD3 with PBS.
The CD3+T cell quantity of duodenum, jejunum is in rising trend in whole duration of immunity, and the independent use of ratio newcastle IV is that Seedling immune group cell quantity extremely significantly increases (P＜0.01) when the 5th week, the 7th week.
2) variation of Peyer ' s speckle intraepithelial lymphocyte
Show intraepithelial lymphocyte with HE dyeing: paraffin section, dimethylbenzene is taken off in dewaxing, the hematoxylin-eosin dye liquor, dehydration, transparent, sealing.The Olympus microscopic examination, take pictures.
Peyer ' s speckle intraepithelial lymphocyte quantity is in rising trend in whole duration of immunity, and " chamber row " phenomenon is arranged.When the 5th week, the 7th week, extremely significantly increase (P＜0.01) than the independent immune group cell quantity of newcastle.
3) jejunum interferon-mRNA level changes
Measure IFN-γ mRNA in the chicken jejunum with relative quantification RT-PCR method: adopt one step of guanidinium isothiocyanate phenol chloroform extraction method to extract the jejunum total tissue RNA.Concentration and the purity (260nm) of the total RNA that extracts with determined by ultraviolet spectrophotometry are identified the quality of total RNA by the degeneration agarose gel electrophoresis.With random primer Random hexamer primer the RNA of all samples is carried out RT, obtain the cDNA (RT product) of each sample RNA.RT reaction cumulative volume 25 μ L, comprise the total RNA of 2 μ g, 20U RNA enzyme inhibitor, 100U M-MLV reverse transcription, 5 μ L, 5 * RT buffer (contains 250mmol/L Tris-HClpH8.3,375mmol/L KCl, 15mmol/L MgCl2,50mmol/L DDT), 0.4mmol/L dNTP, 4 μ mol/L random primers.Add the RNA template earlier, dNTP and random primer are placed on cooled on ice behind 37 ℃ of degeneration 5min immediately, add 37 ℃ of reactions of all the other reagent 60min again, 95 ℃ of deactivation 5min.Go up the chicken IFN-γ mRNA sequential design primer of login according to Genbank (Y07922).IFN-γ forward primer sequence is: 5 ' GAG CCA TCA CCA AGA AGA 3 ', the downstream primer sequence is: 5 ' GAG CAC AGG AGG TCA TAA 3 ', amplification length is 537bp.With 18SrRNA is interior mark, because of interior mark is close with IFN-γ amplification segment size, so adopt two-tube TRAP.PCR reaction volume 25 μ L contain template (RT product) 2 μ L, 0.1 μ L Taq archaeal dna polymerase, 2.5 μ L 10 * PCR Buffer (contains 50mmol/L Tris-HCl pH9.0,100mmol/L NaCl, 1.0mmol/L DDT, 0.1mmol/L EDTA, 500mmol/L glydcerol, 10g/LTriton X-100), 0.5 μ L dNTP, 1.6 μ L MgCl2,2.0 mark in the μ L genes of interest primer, 1.0 μ L 18S rRNA.The pcr amplification condition is: 94 ℃ of pre-degeneration 5min; IFN-γ (94 ℃ of degeneration 30s; 55 ℃ of renaturation 30s; 72 ℃ are extended 30s, totally 38 circulations), 18S (94 ℃ of degeneration 30s; 53 ℃ of renaturation 30s; 72 ℃ are extended 30s, totally 24 circulations); 72 ℃ are extended 10min.The PCR product of 18S and genes of interest is all in the linear amplification scope.Whether each sample is done twice repetition, replaces the RT product respectively with ddH2O and RNA sample simultaneously and does contrast, have exogenous gene group DNA to pollute with check.Get 20 μ LPCR products electrophoresis on the agarose gel of 20g/L, EB dyeing.The Flame Image Process of electrophoresis result and gray analysis carry out on Kodak1D Electrophoresis Documentation and Analysis System 120, according to the gray scale ratio of genes of interest IFN-γ and interior mark 18S PCR product, determine the relative amount that IFN-γ mRNA expresses in the sample.
Jejunum interferon-mRNA expression is on a declining curve, and the composite adjuvant group significantly reduces (P＜0.05) than newcastle group.
2 humoral immunity levels detect
1) ND IgG antibody level changes in the serum
Detect newcastle epidemic disease antibody IgG in the serum with hemagglutination inhibition test: prepare 4 unit viruses with standard newcastle antigen, on 96 hole Sptting plates, add normal saline, serum doubling dilution liquid, 4 units virus and 1% chicken red blood cell successively.Reading behind 37 ℃ of 15min.
Composite adjuvant group antibody can keep higher level in whole duration of immunity, high 2 titres of immunity back 2～4 all average specific newcastle groups.
2) ND antibody I gA level changes in the serum
Detect ND antibody I gA in the serum with the ELISA test: newcastle is antigen coated to spend the night, 37 ℃ of 2h of skimmed milk sealing add 37 ℃ of 1h of serum to be checked after the washing, washing adds the anti-chicken IgA37 ℃ 1h of rabbit, wash 37 ℃ of 1h of enzyme-added mark goat anti-rabbit igg, OPD colour developing back microplate reader detects.
Newcastle epidemic disease antibody IgA level adjuvant group and newcastle group in whole duration of immunity changes not obvious in the serum.
3) ND SIgA level changes in the intestinal contents
Detect newcastle epidemic disease antibody IgA in the serum with the ELISA test: newcastle is antigen coated to spend the night, 37 ℃ of 2h of skimmed milk sealing add 37 ℃ of 1h of content supernatant to be checked after the washing, washing adds the anti-chicken IgA37 ℃ 1h of rabbit, wash 37 ℃ of 1h of enzyme-added mark goat anti-rabbit igg, OPD colour developing back microplate reader detects.
SIgA significantly increased at the immunity initial stage in the intestinal contents, and composite adjuvant can extremely significantly increase the antibody-secreting amount at jejunum.
3. counteracting toxic substances protection test
With composite mucosa immunological adjuvant and newcastle disease vaccine vaccinated flock, totally 24 chickens.Immunity back the 67th day is attacked the chicken group with newcastle virulent strain F48E2.The chicken of composite adjuvant group had 2 slight mental symptoms to occur behind counteracting toxic substances on the 4th day, and other is normal; All normal after the 7th day behind the counteracting toxic substances, survival rate is 100%.The chicken of newcastle group behind counteracting toxic substances the 4th day dead 3, survival rate 50%; Behind the counteracting toxic substances the 5th day dead 2, survival rate 16.67%; All death in the 6th day behind the counteracting toxic substances; The chicken of matched group is all death in the 4th day behind counteracting toxic substances.The result shows, can effectively protect the chicken group after the interpolation composite mucosa immunological adjuvant.
The survival condition of the immune chicken of table 1 after NDF48E2 virulent strain is attacked
| Natural law behind the counteracting toxic substances | Composite adjuvant group survival number of elements/test number of elements | ND immune group survival number of elements/test number of elements | Matched group survival number of elements/test number of elements |
| The 1st day the 2nd day the 3rd day the 4th day the 5th day the 6th day the 7th day the 8th day the 9th day the | 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 | 6/6 6/6 6/6 3/6 1/6 0/6 0/6 0/6 0/6 0/6 | 6/6 6/6 6/6 0/6 0/6 0/6 0/6 0/6 0/6 0/6 |
Use
Two kinds of composite mucosa immunological adjuvants provided by the present invention can be used for multiple oral vaccine, significantly improve the immune effect of vaccine.Sodium fluoride has finished product to sell in the composite adjuvant, and CpG can use after extracting.Simultaneously, the composite adjuvant cost is lower, every average out to 2.5016 minutes.The immunity of newcastle will be that the vaccine collocation is used with IV system and I all usually in present the production, and IV is that the vaccine oral dose need double, and cost is 1.2 minutes/; When 1 monthly age, be vaccine injection with I, cost be 2.0 minutes/only.Need 3.2 fens altogether/only.After using composite adjuvant, can reduce IV is the vaccine consumption, and cost is 0.6 minute/.Usually the commercial meat bird growth cycle is 40 days, and the composite adjuvant group still had 100% protective rate to the chicken group on the 82nd day after immunity, therefore can cancel the use that I is a vaccine, reduced the animal stress, reduced aquaculture cost greatly.Culturing with 10000 broiler is example, is (1.2+2.0) * 10000=320 unit by traditional immunization method cost, if be (2.5016+0.6) * 10000=310 unit with its cost of composite adjuvant, reduction rate is 3.125%.
Claims (2)
1, a kind of composite adjuvant of mucosa-immune uses the immunological adjuvant prescription to be by the body weight per kilogram: 20～100 μ g oligodeoxynucleotide (CpG) DNA+2～10mg sodium fluoride.
According to the composite adjuvant of the described a kind of mucosa-immune of claim 1, it is characterized in that 2, the chickling consumption by every is: 20-100 μ g oligodeoxynucleotide (CpG) DNA+2～10mg sodium fluoride.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200610085420XA CN100402090C (en) | 2006-06-15 | 2006-06-15 | Mucosa-immune composite adjuvant |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200610085420XA CN100402090C (en) | 2006-06-15 | 2006-06-15 | Mucosa-immune composite adjuvant |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1895669A true CN1895669A (en) | 2007-01-17 |
| CN100402090C CN100402090C (en) | 2008-07-16 |
Family
ID=37608412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB200610085420XA Expired - Fee Related CN100402090C (en) | 2006-06-15 | 2006-06-15 | Mucosa-immune composite adjuvant |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100402090C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101085348B (en) * | 2007-06-18 | 2010-08-18 | 南京农业大学 | Nasal cavity immunity composite adjuvant for avian influenza inactivation antigen |
| CN102000332A (en) * | 2010-11-16 | 2011-04-06 | 南京农业大学 | Composite adjuvant for duck bird flu oral mucosal immunization |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1301572A (en) * | 1999-10-28 | 2001-07-04 | 上海生物制品研究所 | Adjuvant composition for vaccine |
| CN100486987C (en) * | 2003-03-05 | 2009-05-13 | 长春华普生物技术有限公司 | Antivira and antitumor deoxyoligonucleotide containing CpG single strand |
-
2006
- 2006-06-15 CN CNB200610085420XA patent/CN100402090C/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101085348B (en) * | 2007-06-18 | 2010-08-18 | 南京农业大学 | Nasal cavity immunity composite adjuvant for avian influenza inactivation antigen |
| CN102000332A (en) * | 2010-11-16 | 2011-04-06 | 南京农业大学 | Composite adjuvant for duck bird flu oral mucosal immunization |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100402090C (en) | 2008-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Embregts et al. | Oral vaccination of fish: Lessons from humans and veterinary species | |
| Sedeik et al. | Comparative efficacy of commercial inactivated Newcastle disease virus vaccines against Newcastle disease virus genotype VII in broiler chickens | |
| Okino et al. | Humoral and cell-mediated immune responses to different doses of attenuated vaccine against avian infectious bronchitis virus | |
| Ifrah et al. | The role of the bursa of Fabricius in the immune response to vaccinal antigens and the development of immune tolerance in chicks (Gallus domesticus) vaccinated at a very young age | |
| Fu et al. | Effects of different CpG oligodeoxynucleotides with inactivated avian H5N1 influenza virus on mucosal immunity of chickens | |
| Zhang et al. | Effect of compound mucosal immune adjuvant on mucosal and systemic immune responses in chicken orally vaccinated with attenuated Newcastle-disease vaccine | |
| Chen et al. | An oral nervous necrosis virus vaccine using Vibrio anguillarum as an expression host provides early protection | |
| Sarcheshmei et al. | Comparative evaluation of the protective efficacy of different vaccination programs against a virulent field strain of the Newcastle Disease virus in broilers | |
| Li et al. | Bursopentine as a novel immunoadjuvant enhances both humoral and cell-mediated immune responses to inactivated H9N2 avian influenza virus in chickens | |
| Ray et al. | A field study on the evaluation of day-of-hatch and in grow-out application of live infectious bursal disease virus vaccine in broiler chickens | |
| Alqazlan et al. | Probiotic lactobacilli enhance immunogenicity of an inactivated H9N2 influenza virus vaccine in chickens | |
| CN102000332B (en) | Composite adjuvant for duck bird flu oral mucosal immunization | |
| Ibe et al. | Alginate-coated chitosan microparticles encapsulating an oral plasmid-cured live Salmonella enterica serovar Gallinarum vaccine cause a higher expression of interferon-gamma in chickens compared to the parenteral live vaccine | |
| CN100402090C (en) | Mucosa-immune composite adjuvant | |
| Mahana et al. | Pathological changes, shedding pattern and cytokines responses in chicks infected with avian influenza-H9N2 and/or infectious bronchitis viruses | |
| Ma et al. | Screening the potential part of the G protein antigen is an achievable strategy to improve the immune effect of DNA vaccine against MSRV infection | |
| CN100388953C (en) | Composite mucosa immunoadjuvant for oral vaccine | |
| EP2113511A1 (en) | Dna vaccines for fish | |
| CN116064548B (en) | Novel CpG vaccine adjuvant and application thereof | |
| CN106215185A (en) | A kind of preparation method of the multi-joint subunit vaccine of Avianreovirus | |
| Barkhordari et al. | Comparison of flagellin and an oil-emulsion adjuvant in inactivated Newcastle disease vaccine in stimulation of immunogenic parameters | |
| KR101518473B1 (en) | Immunogloblin y complex composition for vaccinating or curing canine viral infectious diseases and production method thereof | |
| Okwor et al. | Effects of mixed vaccinations against newcastle disease and infectious bursal disease on immune response, feed consumption and weight gain in broilers | |
| Ahmed et al. | Experimental efficacy evaluation of different vaccination programs for epidemic Newcastle disease virus in Egypt against challenge with velogenic genotype VII 1.1 in commercial broiler chickens | |
| CN101074260A (en) | Production of hygrophilous monospermous bacterium main-protective antigen univalent and multivalent vitelline antibody and use in aquatic animal |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080716 |